Peroxisome proliferator-activated receptor gamma: Difference between revisions
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Latest revision as of 13:05, 18 March 2025
Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG), also known as the glitazone receptor, is a type of nuclear receptor that is of interest for its role in biology and medicine. PPARG regulates fatty acid storage and glucose metabolism. The genes activated by PPARG stimulate lipid uptake and adipogenesis by fat cells.
Function[edit]
PPARG binds peroxisome proliferators and controls the size and number of peroxisomes produced within cells. PPARG is a regulator of adipocyte differentiation, and it also has anti-inflammatory effects and inhibits the vasoconstriction of vascular smooth muscle cells.
Clinical significance[edit]
PPARG has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis, and cancer. PPARG agonists have been used in the treatment of hyperlipidaemia and hyperglycemia.
Ligands[edit]
Several different kinds of ligands can bind to PPARG, including synthetic ligands, naturally occurring fatty acids, and prostaglandins.
See also[edit]
References[edit]
<references />
External links[edit]
- PPARG at the US National Library of Medicine Medical Subject Headings (MeSH)


